Liquidia Corp. saw heightened retail chatter Monday after Bank of America increased its stock price target to $25 from $22 ...

The US Food and Drug Administration (FDA) has approved treprostinil inhalation powder (YUTREPIA), a prostacyclin analog ...

A groundbreaking study has revealed that supplementing vasopressin, a hormone linked to social behavior, may improve social ...

Liquidia Corporation ( NASDAQ: LQDA) said on Friday that the U.S. FDA has approved Yutrepia inhalation powder, a prostacyclin ...

SHANGHAI, May 16, 2025 /PRNewswire/ -- Nuance Pharma ("Nuance") today announces its top-line Phase 3 ENHANCE-CHINA (NCT05743075) trial results evaluating nebulized ensifentrine for the maintenance ...

Lidocaine seems an effective option for relieving procedural pain. The objective of this study was a systematic review with metanalysis to evaluate the analgesic efficacy of jelly, spray, atomized and ...

Thus far, PH-ILD patients in the ASCENT study have been able to titrate to doses that are 3 times higher than the labeled target dose of nebulized Tyvaso. These patients have also shown positive ...

Liquidia Technologies Inc. (NASDAQ:LQDA) reported a larger net loss for Q1 2025 compared to the previous year, despite a slight increase in revenue. The company’s earnings per share (EPS) fell ...

The nebulized mRNA-LNP candidate has nabbed FDA fast track status and aims to tackle the underlying cause of CF by programming cells in the lungs to produce functional CF transmembrane conductance ...